Johnson & Johnson has agreed to pay $1 billion for an 18.4% stake in Irish drugmaker Elan Corp, and will acquire most of the rights to Elan’s portfolio of experimental drugs to treat Alzheimer’s disease.
*For more on this story,
read the full Reuters article.
